Researchers identify potential drug combinations to improve breast cancer treatment: Q&A with professor of pharmacology
Triple-negative breast cancer, an aggressive type of breast cancer, accounts for 10% of all breast cancer cases in the United ...
EurekAlert!5d
A new CAR-T-cell therapy tricks cancer cells with a decoy to increase treatment efficiency in B-cell Acute Lymphoblastic Leukaemia
Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.
Nature5d
T cells articles from across Nature Portfolio
These receptors allow T cells to sense and respond to diverse types of infection. Immune checkpoint blockade therapy for cancer is promising, but delivery optimization is desirable. Here the ...
Technology Networks4d
CAR T Cells Engineered To Release a “Decoy” Show Improved Anti-Cancer Activity
Treatment of B-cell acute lymphoblastic leukemia has improved thanks to CAR T therapies, but relapse is still very common. An ...
CURE10h
Favorable Initial Results in Phase 1 Trial for PD-L1 Resistant Tumors
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...
EurekAlert!8d
A new CAR-T-cell therapy that tricks the tumor could increase treatment efficiency in B-cell Acute Lymphoblastic Leukemia
Treatment of B-cell Acute Lymphoblastic Leukaemia has been greatly improved by CAR-T therapies, but relapse is still very common. An international team has now found in animal models a new approach ...
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response ...
Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn an additional $0.7 with the CVR.
CAR T-cell therapy tricks cancer cells with decoy, increases treatment efficiency in B-cell acute lymphoblastic leukemia
B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...
Nature5d
CD8-positive T cells articles from across Nature Portfolio
identify Elovl1 as a target to improve antitumour immunity by remodelling T cell lipid metabolism. ‘Small cell lung cancers do not respond well to immune checkpoint blockade therapy, due to the ...